Please Wait
Applying Filters...
menu
    • menu
    DRL offers a portfolio of products & services, including APIs, CMO services, generics, biosimilars & differentiated formulations.

    Virtual Booth

    Contact Supplier

    Biophore is a research-driven global pharmaceutical company focused on niche APIs for the generic industry.

    Virtual Booth

    Contact Supplier

    pharmacompass-1-m-2026-01-12

    Virtual Booth

    An Enquiry

    LGM Pharma accelerates & optimizes the new product pathway from early development through commercialization.https://marketing.lgmpharma.com/LGM-CDMO

    Virtual Booth

    Contact Supplier

    Vamsi Labs is one of the major manufacturers of Anti-asthmatic, Anti-migraine & Anti-psychotic APIs.

    Virtual Booth

    Contact Supplier

    pharmacompass-2-2026-02-09

    Virtual Booth

    An Enquiry

    Menu

    Dusquetide

    DEVELOPMENTS

    DIGITAL CONTENT

    PharmaCompass
    Xls

    Filters

    clear-filterReset all filters
    Left Arrow
    Right Arrow

    Digital Content read-more

    Create Content with PharmaCompass, ask us

    NEWS #PharmaBuzz

    read-more
    read-more
    SGX945 Phase 2 Trial Shows Promising Results In Behçet's Disease
    SGX945 Phase 2 Trial Shows Promising Results In Behçet's Disease

    18 Dec 2025

    // PR NEWSWIRE

    https://www.prnewswire.com/news-releases/positive-clinical-results-from-phase-2-trial-of-sgx945-for-the-treatment-of-behcets-disease-published-in-rheumatology-oxford-302645452.html

    PR NEWSWIRE
    18 Dec 2025
    Share Share
    Soligenix Launches Phase 2 Trial for SGX945 in Behçet's Disease
    Soligenix Launches Phase 2 Trial for SGX945 in Behçet's Disease

    14 Nov 2024

    // PR NEWSWIRE

    https://www.prnewswire.com/news-releases/soligenix-initiates-a-phase-2-clinical-trial-of-sgx945-dusquetide-for-the-treatment-of-behcets-disease-302305230.html

    PR NEWSWIRE
    14 Nov 2024
    Share Share
    FDA Grants Soligenix
    FDA Grants Soligenix "Fast Track" Designation for Dusquetide

    08 Jan 2024

    // PRESS RELEASE

    https://ir.soligenix.com/2024-01-08-FDA-Grants-Soligenix-Fast-Track-Designation-for-Dusquetide-in-the-Treatment-of-Oral-Lesions-of-Behcets-Disease

    PRESS RELEASE
    08 Jan 2024
    Share Share
    Key Binding Characteristics of Dusquetide to Intracellular Protein Identified
    Key Binding Characteristics of Dusquetide to Intracellular Protein Identified

    01 Jun 2022

    // PRNEWSWIRE

    https://www.prnewswire.com/news-releases/key-binding-characteristics-of-dusquetide-to-important-intracellular-protein-identified-301558732.html

    PRNEWSWIRE
    01 Jun 2022
    Share Share
    Dusquetide Shows +ve Anti-tumor Efficacy in Multiple Nonclinical Animal Studies
    Dusquetide Shows +ve Anti-tumor Efficacy in Multiple Nonclinical Animal Studies

    04 Jan 2022

    // PRNEWSWIRE

    https://www.prnewswire.com/news-releases/dusquetide-demonstrates-positive-anti-tumor-efficacy-in-multiple-nonclinical-animal-studies-301452943.html

    PRNEWSWIRE
    04 Jan 2022
    Share Share
    Soligenix completes enrollment in phase 3 DOM-INNATE trial of SGX942
    Soligenix completes enrollment in phase 3 DOM-INNATE trial of SGX942

    26 Jun 2020

    // PHARMABIZ

    http://www.pharmabiz.com/NewsDetails.aspx?aid=129139&sid=2

    PHARMABIZ
    26 Jun 2020
    Share Share
    • Privacy policy
    • Terms and conditions
    • Disclaimers
    • LinkedIn
    • Product listings are provided for informational purposes only. We do not supply or sell any products. Any products that may be covered by patent(s) are supplied solely for uses permitted under Section 107A of the Indian Patents Act and not for commercial sale.